Novo Nordisk, the multinational pharmaceutical giant responsible for popular weight loss drugs Ozempic and Wegovy, briefly surpassed LVMH, the French luxury empire, as Europe’s most valuable company. During Friday morning trading in London, Novo Nordisk’s market capitalization reached $421 billion, edging past LVMH, which had a market cap of $420.97 billion. Novo Nordisk’s market cap included unlisted shares that are not available on any stock exchange. However, as the European trading session continued, LVMH’s shares recovered, reclaiming the top spot with a market cap of $423.9 billion, while Novo Nordisk’s market cap stood around $421.9 billion.
Novo Nordisk’s market cap surge can be attributed to the significant increase in its share price over the past three years, which has tripled, compared to a doubling of LVMH’s share price. The surge in Novo Nordisk’s shares can be linked to the positive results of a large study that demonstrated Wegovy’s cardiovascular benefits, diversifying the company’s product image beyond a mere lifestyle drug. Sales of Ozempic, a diabetes drug increasingly used off-label for obesity and heart failure, have skyrocketed, generating $3.2 billion in the second quarter alone, compared to $2.1 billion in the same period last year. Novo Nordisk’s obesity-focused drugs, Wegovy and Saxenda, also experienced a significant sales increase, reaching a combined $1.6 billion in the second quarter.
Other pharmaceutical companies, such as Eli Lilly, are following suit and capitalizing on the growing demand for anti-obesity medications. Eli Lilly’s diabetes drug, Mounjaro, achieved $980 million in sales during the second quarter, a 72% increase compared to the first quarter of this year. Consequently, Lilly’s stock has risen by over 80% in the past year. Meanwhile, LVMH, known for its luxury brands including Louis Vuitton, Dior, Sephora, and Dom Pérignon, reported a decline in sales for the second quarter due to reduced spending on luxury goods among Americans facing inflationary pressures. Concerns over China’s weakening economy have also impacted investor confidence in LVMH. Nonetheless, Bernard Arnault and his family still possess the second-largest fortune globally, with a net worth valued at $186 billion according to the Bloomberg Billionaires Index.
In summary, Novo Nordisk briefly overtook LVMH as Europe’s most valuable company, driven by the success of its weight loss drugs and positive study results. The surge in sales and market capitalization reflects the growing demand for anti-obesity medications across the pharmaceutical industry, with companies like Eli Lilly also experiencing significant growth. On the other hand, LVMH’s sales decline and worries over China’s economic situation have affected its position. However, the Arnault family remains incredibly wealthy, ranking second among the world’s wealthiest individuals.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
